<DOC>
	<DOC>NCT01991678</DOC>
	<brief_summary>The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild, moderate, or severe hepatic impairment.</brief_summary>
	<brief_title>A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)</brief_title>
	<detailed_description>Safety and PK data from patients with mild, moderate, or severe hepatic impairment will be compared with a control group consisting of patients with normal hepatic function.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Relapsed or progressive advanced solid tumor malignancies Measurable or nonmeasurable disease Eastern Cooperative Oncology Group (ECOG) performance status of 02 Life expectancy greater than 3 months Resolution of all acute toxic effects of prior chemotherapy, and other cancer treatments Adequate bone morrow and kidney function No signs of decompensated liver cirrhosis or ascites requiring therapeutic paracentesis Agree to use adequate contraception Previous chemotherapy, immunotherapy, chemoembolization, targeted therapy or investigational agent for malignancy within 4 weeks prior to day 1 Cytochrome P450 CYP3A4 inducers and inhibitors within 4 weeks prior to day 1 Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing grapefruit or Seville oranges within 14 days prior to day 1 UGT1A1 genotype of TA 7 in both alleles (homozygous UGT1A1*28) or TA 8 in either one or both alleles (hetero or homozygous for UGT1A1*37) Major surgery within 4 weeks prior to day 1 Undergone a liver or other organ transplant Concurrent treatment with other anticancer therapy Untreated central nervous system metastases Ongoing or active infection Chronic or acute GI disorders resulting in diarrhea Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>